Lepirudin
Lepirudin is a recombinant direct thrombin inhibitor historically used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT) who require prevention or treatment of thromboembolic complications. It works by binding directly and irreversibly to thrombin, inhibiting the conversion of fibrinogen to fibrin and preventing blood clot formation. It was supplied as a powder for reconstitution and administered by intravenous infusion under hospital supervision. Potential adverse effects include bleeding, injection-site or infusion-related reactions, and allergic responses, particularly with repeat exposure. Treatment requires close monitoring of coagulation parameters, typically activated partial thromboplastin time (aPTT), as well as renal function because lepirudin is primarily eliminated by the kidneys. Lepirudin is a discontinued or unavailable product in many markets, so its current regulatory status and availability should be confirmed before considering it for clinical or import purposes.
Lepirudin was historically used as a respiratory medicine for the symptomatic management of certain respiratory conditions. Its former uses included:
is okay
The import of medicines into India is regulated by the Central Drugs Standard Control Organisation (CDSCO) under the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The regulatory requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished formulation, or an unapproved medicine intended for an individual patient's treatment.
Primeera Healthcare Private Limited can provide import coordination and pharmaceutical documentation assistance for Lepirudin, subject to confirmation of its current regulatory status and eligibility for import into India.
The export of Lepirudin from India is subject to applicable requirements under the Drugs and Cosmetics Act, 1940, the Drugs and Cosmetics Rules, 1945, and relevant export, customs, and destination-country regulations. Documentation requirements depend on whether the product is an active pharmaceutical ingredient (API), a finished pharmaceutical formulation, or a medicine intended for a specific market. Export eligibility and destination-country requirements must be verified before shipment.
Primeera Healthcare Private Limited can provide pharmaceutical export documentation assistance, regulatory coordination, and shipping support for Lepirudin, subject to confirmation of its export eligibility under applicable Indian regulations and the import requirements of the destination country.
If you have any questions or need any help, contact our Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
All Trademarks and Brands that appear on the website belong to their respective owners. Primeera Healthcare does not lay any claim on them; we only provide information.
